search
Back to results

MaxART: Early Access to ART for All in Swaziland (MaxART)

Primary Purpose

HIV/AIDS

Status
Completed
Phase
Not Applicable
Locations
Swaziland
Study Type
Interventional
Intervention
Early Access to ART for All
Sponsored by
Clinton Health Access Initiative Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for HIV/AIDS focused on measuring HIV/AIDS, Swaziland

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • All ART-naive HIV-positive individuals who are 18 years of age or older - excluding pregnant or breastfeeding women - who attend the health facilities included in the study will be asked for their consent to enroll in the study.

Exclusion Criteria:

  • All HIV-positive individuals who < 18 years of age or older and pregnant or breastfeeding women.
  • All HIV-positive individuals who did not consent to participate or who have already been initiated on ART.

Sites / Locations

  • Swaziland Ministry of Health

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

National HIV Treatment Guidelines

Early Access to ART for All

Arm Description

HIV-positive individuals are offered ART per Swaziland's national treatment guidelines

HIV-positive individuals are initiated on ART regardless of client's immunological and clinical staging

Outcomes

Primary Outcome Measures

Retention
Proportion of individuals retained in care or on ART at 12 months
Viral suppression
Proportion of individuals whose viral load is below 1,000 copies/ml (virally suppressed) after 6 months on ART

Secondary Outcome Measures

12-month mortality rate
mortality rate among clients newly enrolled in or returning to facilities during the standard of care phase is equal to 12-month mortality rate among clients newly enrolled in or returning to facilities during early ART phase
Visit adherence among those initiated on ART
Proportion of missed visits as a number of scheduled appointments among ART-ineligible clients by end of follow-up
Drug resistance
Proportion of drug resistance among ART-ineligible clients with two virological failures who have received genotype resistance testing
Tuberculosis
Proportion of HIV-positive individuals diagnosed with new tuberculosis following enrollment (recurrent and newly incident).
ART uptake among those who are eligible
Proportion of HIV-positive individuals who are eligible for initiation who are successfully initiated to ART within 1 and 3 months of becoming eligible
Cost per patient per year
Bottom-up and top-town costing of the patient lifetime cost to test, treat, link, and retain individuals on ART
HIV infection
Mathematical modeling to estimate the number of new adult HIV infections using empirical data from the primary endpoints

Full Information

First Posted
July 10, 2016
Last Updated
July 17, 2018
Sponsor
Clinton Health Access Initiative Inc.
Collaborators
Ministry of Health, Swaziland, STOP AIDS NOW! (SAN!), Swaziland National Network of People Living with HIV/AIDS (SWANNEPHA), Southern African AIDS Information Dissemination Service (SAfAIDS), Southern African Centre for Epidemiological Modelling and Analyses (SACEMA), University of Amsterdam, Harvard School of Public Health (HSPH)
search

1. Study Identification

Unique Protocol Identification Number
NCT02909218
Brief Title
MaxART: Early Access to ART for All in Swaziland
Acronym
MaxART
Official Title
MaxART: Early Access to ART for All in Swaziland
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
September 1, 2014 (Actual)
Primary Completion Date
August 31, 2017 (Actual)
Study Completion Date
August 31, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clinton Health Access Initiative Inc.
Collaborators
Ministry of Health, Swaziland, STOP AIDS NOW! (SAN!), Swaziland National Network of People Living with HIV/AIDS (SWANNEPHA), Southern African AIDS Information Dissemination Service (SAfAIDS), Southern African Centre for Epidemiological Modelling and Analyses (SACEMA), University of Amsterdam, Harvard School of Public Health (HSPH)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the feasibility, acceptability, clinical outcomes, affordability, and scalability of offering early antiretroviral treatment to all HIV-positive individuals in Swaziland's government-managed health system.
Detailed Description
The clinical evidence in support of offering antiretroviral treatment (ART) for all HIV-positive individuals to improve patient health outcomes and reduce HIV incidence is building, and the resource-limited countries where this approach could have the biggest impact want to evaluate if this is a feasible and effective intervention to turn the course of their HIV epidemics. The MaxART Early Access to ART for All (EAAA) implementation study was designed to determine the feasibility, acceptability, clinical outcomes, affordability, and scalability of offering early antiretroviral treatment to all HIV-positive individuals in Swaziland's government-managed health system. This is a 3-year randomized stepped wedge design with open enrollment for all adults 18 years and older across 14 rural health facilities in Swaziland's Hhohho Region. Primary endpoints are retention and viral suppression. Secondary endpoints include ART initiation, adherence, drug resistance, tuberculosis, HIV disease progression, and cost per patient per year. Sites are grouped to transition two at a time from the control (standard of care) to intervention (EAAA) stage at each 4-month step. This balanced design will result in approximately one half of the observations being under an intervention clinic, and the other half under control. Power calculations were conservatively based on the estimated number of individuals expected to enroll in the study comparing the first 12-month measure of retention and 6-month of viral suppression on ART of those entering clinics during their control stage versus those that will be entering a clinic during intervention period. A strategic mix of multidisciplinary research methodologies will be applied to meet the study aim, including implementation science, social science research, economic evaluations, and HIV incidence modeling.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV/AIDS
Keywords
HIV/AIDS, Swaziland

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
3485 (Actual)

8. Arms, Groups, and Interventions

Arm Title
National HIV Treatment Guidelines
Arm Type
No Intervention
Arm Description
HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
Arm Title
Early Access to ART for All
Arm Type
Experimental
Arm Description
HIV-positive individuals are initiated on ART regardless of client's immunological and clinical staging
Intervention Type
Other
Intervention Name(s)
Early Access to ART for All
Intervention Description
All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines.
Primary Outcome Measure Information:
Title
Retention
Description
Proportion of individuals retained in care or on ART at 12 months
Time Frame
12 months
Title
Viral suppression
Description
Proportion of individuals whose viral load is below 1,000 copies/ml (virally suppressed) after 6 months on ART
Time Frame
6 months
Secondary Outcome Measure Information:
Title
12-month mortality rate
Description
mortality rate among clients newly enrolled in or returning to facilities during the standard of care phase is equal to 12-month mortality rate among clients newly enrolled in or returning to facilities during early ART phase
Time Frame
12 months
Title
Visit adherence among those initiated on ART
Description
Proportion of missed visits as a number of scheduled appointments among ART-ineligible clients by end of follow-up
Time Frame
36 months
Title
Drug resistance
Description
Proportion of drug resistance among ART-ineligible clients with two virological failures who have received genotype resistance testing
Time Frame
36 months
Title
Tuberculosis
Description
Proportion of HIV-positive individuals diagnosed with new tuberculosis following enrollment (recurrent and newly incident).
Time Frame
36 months
Title
ART uptake among those who are eligible
Description
Proportion of HIV-positive individuals who are eligible for initiation who are successfully initiated to ART within 1 and 3 months of becoming eligible
Time Frame
3 months
Title
Cost per patient per year
Description
Bottom-up and top-town costing of the patient lifetime cost to test, treat, link, and retain individuals on ART
Time Frame
12 months
Title
HIV infection
Description
Mathematical modeling to estimate the number of new adult HIV infections using empirical data from the primary endpoints
Time Frame
36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All ART-naive HIV-positive individuals who are 18 years of age or older - excluding pregnant or breastfeeding women - who attend the health facilities included in the study will be asked for their consent to enroll in the study. Exclusion Criteria: All HIV-positive individuals who < 18 years of age or older and pregnant or breastfeeding women. All HIV-positive individuals who did not consent to participate or who have already been initiated on ART.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Velephi Okello, MD
Organizational Affiliation
Ministry of Health, Swaziland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Swaziland Ministry of Health
City
Mbabane
Country
Swaziland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33107430
Citation
Briggs J, Teyssier N, Nankabirwa JI, Rek J, Jagannathan P, Arinaitwe E, Bousema T, Drakeley C, Murray M, Crawford E, Hathaway N, Staedke SG, Smith D, Rosenthal PJ, Kamya M, Dorsey G, Rodriguez-Barraquer I, Greenhouse B. Sex-based differences in clearance of chronic Plasmodium falciparum infection. Elife. 2020 Oct 27;9:e59872. doi: 10.7554/eLife.59872.
Results Reference
derived
PubMed Identifier
33074097
Citation
Mobegi FM, Leong LE, Thompson F, Taylor SM, Harriss LR, Choo JM, Taylor SL, Wesselingh SL, McDermott R, Ivey KL, Rogers GB. Intestinal microbiology shapes population health impacts of diet and lifestyle risk exposures in Torres Strait Islander communities. Elife. 2020 Oct 19;9:e58407. doi: 10.7554/eLife.58407.
Results Reference
derived
PubMed Identifier
32831169
Citation
Steinert JI, Khan S, Mlambo K, Walsh FJ, Mafara E, Lejeune C, Wong C, Hettema A, Ogbuoji O, Vollmer S, De Neve JW, Mazibuko S, Okello V, Barnighausen T, Geldsetzer P. A stepped-wedge randomised trial on the impact of early ART initiation on HIV-patients' economic outcomes in Eswatini. Elife. 2020 Aug 24;9:e58487. doi: 10.7554/eLife.58487.
Results Reference
derived
PubMed Identifier
28821264
Citation
Walsh FJ, Barnighausen T, Delva W, Fleming Y, Khumalo G, Lejeune CL, Mazibuko S, Mlambo CK, Reis R, Spiegelman D, Zwane M, Okello V. Impact of early initiation versus national standard of care of antiretroviral therapy in Swaziland's public sector health system: study protocol for a stepped-wedge randomized trial. Trials. 2017 Aug 18;18(1):383. doi: 10.1186/s13063-017-2128-8.
Results Reference
derived

Learn more about this trial

MaxART: Early Access to ART for All in Swaziland

We'll reach out to this number within 24 hrs